Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
To observe in a randomized prospective pilot study the effectiveness and toxicity of
Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD)
kidneys, compared with our standard treatment protocol of Zenapax® and maintenance
immunosuppression
Phase:
Phase 4
Details
Lead Sponsor:
University of Miami
Collaborator:
Hoffmann-La Roche
Treatments:
Alemtuzumab Calcineurin Inhibitors Daclizumab Immunoglobulin G Thymoglobulin